|
We Are Passionate About Our Mission to Reduce the Incidence of Late Stage Cancer
Our next-generation test, Aristotle™, is a panel for simultaneously screening for multiple cancers from a single blood sample. Aristotle was recently selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology. (TSX:SZLS) |
|
|
Investor RelationsWe are StageZero Life Sciences (TSX: SZLS) and we are dedicated to finding cancer in the earliest stages when it is most curable. Our next-generation test, Aristotle™, is a panel for simultaneously screening for multiple cancers from a single blood sample. Aristotle has been built on the company's mRNA Sentinel Principle Technology Platform, which was used to develop one of the first commercially available blood tests for Colorectal Cancer, ColonSentry®.
In The NewsStageZero Life Sciences was recently featured on BNN Bloomberg.
Press Releases |
|
Investor Relations Contacts
James R. Howard-Tripp Chairman and CEO jht@stagezerols.com Rebecca Greco Investor Relations rgreco@stagezerols.com 1-855-420-7140 ext 1838 Corporate Headquarters 30-70 East Beaver Creek Road Richmond Hill, ON L4B 3B2 contact@stagezerols.com |
Stay In Touch! Subscribe to Our Investor Updates |
